Public release date: 5-Sep-2012 [ | E-mail | Share ] Contact: Matthew Chin mchin@support.ucla.edu 310-206-0680 University of California - Los Angeles A multidisciplinary team of researchers from UCLA and other universities is poised to help turn science fiction into reality in the form of some of the world's tiniest electromagnetic devices thanks to a major grant from the National Science Foundation's Engineering Research Center (ERC) program. The grant, worth up to $35 million over 10 years, will fund a new center headquartered at UCLA's Henry Samueli School of Engineering and Applied Science that will focus on research aimed at developing highly efficient and powerful electromagnetic systems roughly the size of a biological cell systems that can power a range of devices, from miniaturized consumer electronics and technologies important for national security to as-yet unimagined machines, like nanoscale submarines that can navigate through the human blood stream. Employing a fundamentally new approach to electromagnetic power at the nanoscale, researchers at the NSF-funded TANMS center (Translational Applications of Nanoscale Multiferroic Systems) are working to replace traditional wire-based electronics with a revolutionary technique that couples electricity and magnetism by using multiferroic materials, which can be magnetically switched "on" and "off" by an electric … Continue reading →

NEW YORK--(BUSINESS WIRE)-- Manhattan Scientifics, Inc. (MHTX), developer of patented technology for early cancer detection, announced it will auction Andy Warhol's original Polaroid of Senator Edward Kennedy to advance cancer research. Warhol used the iconic image to create his silkscreen portrait series supporting the lawmaker's 1980 Presidential campaign. Kennedy died in 2009, after a lengthy battle with brain cancer. Swann Galleries will feature the never-before-seen Polaroid in a New York City auction on Thursday, October 4, 2012. The auction coincides with this year's Presidential race, marking Kennedy's 80th birthday and the 50th anniversary of his seating in the U.S. Senate. These milestones will spark significant bidding interest. Auction proceeds will benefit The Early Use Fund, a non-profit organization assisting leading cancer researchers and prestigious medical facilities, including Memorial Sloan-Kettering and M.D. Anderson, in obtaining access to emerging cancer technologies. One promising breakthrough technology is a method to identify early-stage cancer, developed by scientist Edward R. Flynn and researchers at the University of New Mexico, and funded by Manhattan Scientifics. "This auction remembers the energy and charisma of Ted Kennedy, as seen through the camera lens of artist Andy Warhol," CEO Manny Tsoupanarias said. "Manhattan Scientifics is committed to defeating this … Continue reading →

NEW YORK, Sept. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: http://www.reportlinker.com/p0958105/Drug-Discovery-Technologies-BCC-Research.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development INTRODUCTION In general, the scientific and biotechnology community has seen many breakthrough technologies in the last decade. Surprisingly, there is a big gap between the initial introduction of new platforms and their further application and commercial success. Many analysts and industry insiders are trying to understand the reasons why, in spite of technological advancement, the pharmaceutical industry does not provide more successful drugs and why certain technologies fail to advance or accelerate the drug discovery process. It is important to note that biological and pathological conditions are very complex. Therefore, in order to understand properly the effect of a technology or platform in drug discovery application, the market should be divided into main categories such as, for example, genomics or proteomics-based approaches and their related drug discovery technologies. Each sector has its novel trends and challenges that affect the drug discovery market in general and specific segments in particular. Market participants vary among the different niches in the drug discovery industry. There is also a clear division between technology developers, manufacturer/ suppliers, and biotech companies. Each type of market … Continue reading →